Features & Characteristics Main Features: Energy distribution: Protein 7% Carbohydrate 57% Fat (MCT 4% / LCT 96%) 36% Additional Details: Ordering & Reimbursement Neocate Spoon is available to healthcare professionals to sample in single-serving packets
D.TownsendD
Nausea and dizziness Some researchers experience transient nausea or dizziness, particularly immediately after injection
Specifically, we used a 128-dense layer to embed the input topic mixture before passing it to the two 128-GRU layers followed by a dense layer connected to the CCS medical code output classes
Table 18: Treatment Effects for the Primary Endpoints* and their Components* in the DECLARE Trial Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Received: 13-Jul-2020 Published: 03-Apr-2021, DOI: 10.35248/2155-6156.21.12.869 Copyright: 2021 Wagih NF, et al
